The mRNA moment of 2020-2021 made the message famous, but the patents that matter most cover the envelope, and Translate Bio's 2021 grants make that explicit. US11185595B2 and its siblings US11052159B2 and US10888626B2 - all titled "Lipid nanoparticle compositions and methods for mRNA delivery" and issued in 2021 - claim the LNP composition itself.

Read the CPC tags and the claim center is obvious: A61K 9/1271 and A61K 9/1272 (liposome/nanoparticle formulations), A61K 48/0008 (genetic-material delivery). These are formulation classes. The encoded protein - the part the public hears about - is largely incidental to the claim; what is claimed is the lipid composition that gets any mRNA into cells.

“Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.”— U.S. Patent No. 11,185,595 source

Why does the vehicle carry the invention? Because naked mRNA is fragile and immunogenic; the enabling step was the ionizable-lipid nanoparticle that protects it and releases it inside the cell. The claim limitation that decides scope is the lipid composition - the specific components and ratios - not the sequence of the cargo.

The family pattern is itself informative. Multiple grants in one year with nearly identical titles and overlapping CPC profiles is the signature of a continuation strategy: the assignee files repeatedly off one specification to claim the composition from several angles, building redundancy against any single claim being narrowed. A reader should treat these as one family, not three independent inventions.

For freedom-to-operate, the consequence is that an mRNA therapeutic's biggest IP exposure is rarely its sequence - it is the delivery formulation. Programs cleared the cargo and then collided with the LNP estate, which is why the 2020-2021 lipid-nanoparticle grants from Translate Bio, Moderna, Alnylam, and Acuitas became the most heavily-licensed corner of the field.